Goldman Sachs has begun to cover a quickly growing, high-margin health tech sector that it claims to be set for a post-pandemic increase.According to a research letter published on Wednesday, the Wall Street firm’s experts have issued the stock ratings in the diagnostics sector for the first time and selected four companies that they said are advanced and can expand incomes across multiple products.
Testing for coronavirus has become a part of everyday life for many people, and it has meant the agreement process for such tools has been sped up. As a result, says Goldman, companies in the diagnostics sector are expected to come out of the pandemic “stronger and faster growing,” enhanced by the faster approvals processes for health tests as well as inexpensive technology and more demand from a mature population.
Shareholders receive a 2.98% dividend. The Goldman Sachs price mark for the shares is $277, and the Wall Street consensus price goal is $240.32 per share. Analysts and researchers are very positive and will continue making profits even during the pandemic and after the pandemic ends.